Wednesday, November 18, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
How to earnPaparazzi InkBack PageHolder perksLeaderboardAssignmentsContestsLeagueCity
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsCity LeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundToken utilityRobinhood Chain launchesRobinhood Chain projectsPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 61

FDA clears Sunharbo, first factor XIa inhibitor to prevent second strokes

The FDA approved Sunharbo (asundexian) 50 mg tablets alongside antiplatelet therapy for adults who recently had a mild-to-moderate noncardioembolic ischemic stroke or a high-risk TIA. It's the first factor XIa inhibitor greenlit for use with antiplatelets, backed by a 12,327-patient phase 3 trial that cut ischemic stroke risk by 26%.

By the Paparazzi desk November 17, 2026 · 6:21 PM · medicalxpress.com · 1 view
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: medicalxpress.com.
  • The source published it on Nov 17, 2026 at 6:21 PM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

The FDA has approved Sunharbo (asundexian) 50 mg tablets, taken with antiplatelet therapy, to lower stroke risk in adults who recently suffered a mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack. It becomes the first factor XIa inhibitor cleared for use alongside antiplatelet therapy.

The green light rests on OCEANIC-STROKE, a phase 3 study that randomized 12,327 adults within 72 hours of symptom onset. Participants had a noncardioembolic ischemic stroke scoring 15 or lower on the NIH Stroke Scale, or a high-risk TIA, and all received antiplatelet therapy on top of either Sunharbo or placebo. Sunharbo 50 mg once daily cut the risk of ischemic stroke by 26% compared with placebo across a median treatment period of 14.2 months.

Sponsored

Bleeding looked broadly comparable between the two arms, though major bleeding ticked up with Sunharbo in patients older than 75 and during the first 90 days of treatment. Diarrhea was the most commonly reported adverse reaction, hitting at least 3% of Sunharbo-treated patients, and gastrointestinal bleeding showed up more often than with placebo.

The label carries several limits. Combining Sunharbo with medicines that are both P-gp and strong CYP3A4 inducers isn't recommended because it weakens the drug's effectiveness, and it isn't advised for patients with moderate or severe hepatic impairment. The FDA also did not approve it for stroke prevention in people with atrial fibrillation.

Ashkan Shoamanesh, M.D., co-principal investigator of OCEANIC-STROKE at McMaster University, framed the timing in a statement: the danger of a repeat event is steepest in the days and weeks right after a first stroke, and it never fully fades. He called Sunharbo an important new addition to poststroke care that can help patients reduce the risk of a secondary stroke.

Price since story
TIA+0.14%
Market data, not advice.

TopicsFDA · Sunharbo · asundexian · OCEANIC-STROKE · Ashkan Shoamanesh · McMaster University

Share

Source: medicalxpress.com

Written by AI from verified reporting. Not financial advice.

More stories

  • Health & science 1 hour ago · medicalxpress.com · 0 views
    FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
  • Health & science 4 hours ago · france24.com · 1 view
    WHO warns drug resistance is outpacing the world's response
  • Health & science 7 hours ago · aol.com · 2 views
    FDA Approves Beren's LEMBAZ, First Drug to Improve Survival in Infantile NPC
  • Health & science 8 hours ago · fiercepharma.com · 1 view
    GSK's Nelkarmi wins FDA nod for ALK lung cancer, capping a three-approval run
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.